Dana-Farber Cancer Institute investigators describe a personalized cancer vaccine trial in kidney cancer that was published in Nature. All nine patients did not see their cancer recur.
Toni Choueiri and Patrick Ott describe how this peptide-based vaccine was personalized to numerous neoantigens for the patients in this adjuvant setting trial. Plus, next steps in various cancers.
.png){kind=logo}
